Literature DB >> 7059990

Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.

A Mazumder, E A Grimm, H Z Zhang, S A Rosenberg.   

Abstract

Human peripheral blood lymphocytes (PBL), obtained from patients with a variety of cancers, were incubated in vitro with phytohemagglutinin, concanavalin A, and crude or lectin-free T-cell growth factors. The lectin-activated PBL of nine patients were capable of lysing fresh autologous tumor during a 4-hr 51Cr release assay. Multiple metastases from the same patient were equivalently lysed by these activated autologous PBL. No lysis of fresh PBL or lectin-induced lymphoblast cell targets was seen, although tumor, PBL, and lymphoblast cells were shown to be equally lysable using allosensitized cells. The activated cells could be expanded without loss of cytotoxicity in crude or lectin-free T-cell growth factors. The generation of cells lytic to fresh autologous tumor was dependent on the presence of adherent cells, although the lytic cell itself was not adherent. Proliferation was not involved in the induction of lytic cells since equal lysis was induced in irradiated and nonirradiated lymphocytes. Lectin was not required in the lytic assay, and the addition of alpha-methyl-D-mannoside to concanavalin A-activated lymphoid cells did not increase the lysis of fresh tumor cells. Activation by lectin for 3 days appears to be an efficient and convenient method for generating human cells lytic to fresh autologous tumor. These lytic cells may be of value for studies of the cell-mediated lysis of human tumor and possibly for tumor immunotherapy as well.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059990

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.

Authors:  S Q Liu; L S Liu; T Ohno
Journal:  Cytotechnology       Date:  1998-01       Impact factor: 2.058

2.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

Review 3.  State of melanoma: an historic overview of a field in transition.

Authors:  Vikram C Gorantla; John M Kirkwood
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

Review 4.  Role of IL-2 in cancer immunotherapy.

Authors:  Tao Jiang; Caicun Zhou; Shengxiang Ren
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

5.  Effect of arginase on splenic killer cell activity in patients with gastric cancer.

Authors:  C W Wu; C W Chi; C K Ho; S L Chien; W Y Liu; F K P'eng; S R Wang
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

Review 6.  Activation of lymphocyte anti-tumor responses in man. Towards an understanding of effector cell heterogeneity?

Authors:  B M Vose
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 7.  The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.

Authors:  S A Rosenberg
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

Review 8.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

9.  Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.

Authors:  A Mazumder; E A Grimm; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Lysis of fresh human tumour cells by autologous tumour-associated lymphocytes: two distinct types of autologous tumour killer cells induced by co-culture with autologous tumour.

Authors:  A Uchida; M Moore
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.